Browsing tag:

melanoma


Impressive news was revealed from Roche and Exelixis on June 14, 2014 with successful Phase III study results from their melanoma trial. This comprehensive trial involved Exelixis’s Cobimetinib and Zelboraf, which is marketed by Roche, for treating patients with advanced cases of melanoma. All of the 495 patients had specific mutations of the BRAF gene[…]

Read More

Pfizer and GlaxoSmithKline Combat Melanoma An announcement was made by pharmaceutical giants Pfizer and GlaxoSmithKline at the end of November 2013 regarding their agreement to combine efforts in researching a novel melanoma treatment. The clinical study the two companies have commenced involves adult patients with unresectable, metastatic melanoma. This partnership will be a Phase I/II[…]

Read More

The advent of the FDA Safety and Innovation Act of 2012 has led to an onslaught of new cancer treatments waiting to be approved. Now that the FDA can legally create a new status, known as a “breakthrough” designation, patients with life-threatening diseases such as cancer can obtain their medications faster and more efficiently. However,[…]

Read More

February 8, 2013 – Pomalidomide Now Approved by the FDA to Treat Multiple Myeloma under the FDA’s accelerated approval program. Pomalidomide therapy was also granted orphan product designation as it is intended to treat a rare disease.  Marketed as Pomalyst by Celgene, Pomalidomide, CAS 19171-19-8, is a last chance treatment for patients with Multiple Myeloma[…]

Read More